{"@context":"https://schema.org","@graph":[{"@id":"https://thehippiescientist.net/compounds/semaglutide/#entity","@type":["ChemicalSubstance","MolecularEntity"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"evidence tier","value":"Editorial grade not demonstrated by recorded studies"},{"@type":"PropertyValue","propertyID":"AI entity completeness score","value":34}],"category":"GLP-1 receptor agonist (prescription drug)","description":"Semaglutide is a GLP-1 receptor agonist, FDA-approved as Ozempic, Wegovy, and Rybelsus, backed by a large multi-trial Phase 3 program spanning weight management, type 2 diabetes, cardiovascular risk reduction, and kidney outcomes — a categorically stronger evidence tier than the RUO peptides elsewhere in this series.","identifier":[{"@type":"PropertyValue","propertyID":"THS entity id","value":"ths:compound:semaglutide"},{"@type":"PropertyValue","propertyID":"THS slug","value":"semaglutide"}],"mentions":[{"@id":"https://thehippiescientist.net/compounds/tirzepatide/#entity","@type":["ChemicalSubstance","Thing"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"relationship type","value":"related-to"}],"name":"Tirzepatide","url":"https://thehippiescientist.net/compounds/tirzepatide/"}],"name":"Semaglutide","subjectOf":{"@id":"https://thehippiescientist.net/compounds/semaglutide/#evidence-data"},"url":"https://thehippiescientist.net/compounds/semaglutide/"},{"@id":"https://thehippiescientist.net/compounds/semaglutide/#evidence-data","@type":"Article","about":{"@id":"https://thehippiescientist.net/compounds/semaglutide/#entity"},"author":{"@type":"Person","name":"Willie B. Randolph III","url":"https://thehippiescientist.net/info/author/","@id":"https://thehippiescientist.net/info/author/#person","affiliation":{"@id":"https://thehippiescientist.net/#organization"}},"dateModified":"2026-06-30","dateReviewed":"2026-06-30","description":"Semaglutide is a GLP-1 receptor agonist, FDA-approved as Ozempic, Wegovy, and Rybelsus, backed by a large multi-trial Phase 3 program spanning weight management, type 2 diabetes, cardiovascular risk reduction, and kidney outcomes — a categorically stronger evidence tier than the RUO peptides elsewhere in this series.","headline":"Semaglutide evidence, safety, and entity data","mainEntity":{"@id":"https://thehippiescientist.net/compounds/semaglutide/#entity"},"mentions":[{"@id":"https://thehippiescientist.net/compounds/tirzepatide/#entity","@type":["ChemicalSubstance","Thing"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"relationship type","value":"related-to"}],"name":"Tirzepatide","url":"https://thehippiescientist.net/compounds/tirzepatide/"}],"publisher":{"@type":"Organization","name":"The Hippie Scientist","url":"https://thehippiescientist.net","@id":"https://thehippiescientist.net/#organization"},"url":"https://thehippiescientist.net/compounds/semaglutide/"}]}